Acer Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.61 M
- Company Age 11 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
About Acer Pharmaceuticals
Acer Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 December 2013 and has a history of 11 years and one month. Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.61 M.
The company currently has active open charges totaling ₹2.50 M.
Moorthy Sasirekha and Ezilarasan Bala serve as directors at the Company.
Company Details
-
Location
Tiruvallur, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33100TN2013PTC094085
-
Company No.
094085
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Dec 2013
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
What products or services does Acer Pharmaceuticals Private Limited offer?
Acer Pharmaceuticals Private Limited offers a wide range of products and services, including Personal Protective Equipment, PPE Kits, Face Mask, Cotton Face Mask, 3 Ply Face Mask, Safety Goggles, Safety Glasses, Soap & Sanitizer Dispenser, Foot Operated Sanitizer Dispenser, N95 Mask.
Who are the key members and board of directors at Acer Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Moorthy Sasirekha
|
Director | 06-Dec-2013 | Current |
|
Ezilarasan Bala
|
Director | 06-Dec-2013 | Current |
Financial Performance of Acer Pharmaceuticals.
Acer Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acer Pharmaceuticals?
In 2017, Acer Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Oct 2018 | Syndicate Bank | ₹2.50 M | Open |
How Many Employees Work at Acer Pharmaceuticals?
Unlock and access historical data on people associated with Acer Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acer Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acer Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
